Phadia US Inc.

Phadia US Inc.'s Immunodiagnostics Division supplies in-vitro diagnostic equipment, reagents, and immunological testing services to federal defense and healthcare agencies as a prime contractor, with no subcontract footprint. The division is a foreign-owned, for-profit subsidiary of Thermo Fisher Scientific, headquartered in Portage, Michigan, competing exclusively in full-and-open procurements with no set-aside designations across its federal portfolio.

The division's capability set centers on allergen-specific immunoglobulin E (IgE) antibody testing equipment and reagents for allergy and autoimmune disease diagnosis. Primary products include the IMMUNOCAP 1000 and PHADIA 1000 system analyzers (fully automated immunocap systems), IMMUNOCAP SPEC reagents and conjugates, Helios ANA (antinuclear antibody) testing equipment and reagents, and specimen galactose testers. Representative work includes a $6.07 million lease agreement awarded by the Defense Health Agency in July 2026 for two fully automated Phadia 1000 system analyzers, maintenance, technical support, reagents, and consumables for allergy testing across Lackland Air Force Base through July 2029; a $596,484 purchase order from the Defense Health Agency in October 2023 for allergy testing analyzers and reagents to support Tripler Army Medical Center in Hawaii through September 2026; and a $99,163 purchase order from Veterans Integrated Service Network 22 in March 2026 for Helios ANA testing system reagents, supplies, and service for autoimmune diagnostic support through August 2027.

Customer concentration sits heavily with defense medical organizations. The top five funding agencies account for 83% of awards, dominated by the Department of the Army Medical Command (78 awards, $28.8 million combined potential value) and the Air Force Air Education and Training Command (4 awards, $33.6 million combined potential value), with the Defense Health Agency (30 awards, $8.4 million), Veterans Health Administration VISNs (2 awards, $248 thousand), and the CDC Morgantown (9 awards, $127 thousand) rounding the active set. By potential value, the Air Force leads at $33.6 million (anchored by two single-award BPAs valued at $13.8 million each), followed closely by Army Medical Command at $28.8 million — a reversal from volume ranking that reflects the Air Force's larger per-award dollar magnitudes.

The division holds a $13.8 million single-award Blanket Purchase Agreement with Air Education and Training Command awarded October 1, 2024, extending through October 30, 2026, for two Phadia-owned IMMUNOCAP 1000 analyzers on-site at Wilford Hall Ambulatory Surgical Center (WHASC), JBSA-Lackland, Texas, inclusive of equipment, software, supplies, training, and technical support. Multiple Defense Health Agency BPA calls draw against this vehicle (27 task orders, $1.2 million combined potential value). Additional parent vehicles include an Army Medical Command BPA (W9114F11A0003) with 22 task orders for $103 thousand, an Army Medical Command IDV (W9114F16A0007) with 9 task orders for $3.1 million, and two Army Medical Command indefinite delivery contracts (W91YU006D0022 and W81K0007D0003) with 11 combined task orders for $1.4 million. Nearly all recent calls are firm fixed-price allergy testing supplies and reagents completing by September 30, 2025 or 2026, with work performed from the Portage, Michigan facility.

Activity has accelerated sharply in 2025 and 2026 — two awards in 2021 to fourteen in 2025 and seventeen in 2026 (year-to-date through August 31, 2026) — driven primarily by sustained Defense Health Agency and Army Medical Command BPA call volume. The $71.9 million combined potential value is conservatively obligated, with only $19.9 million (28%) currently obligated across all awards, leaving $52 million in option capacity. A minimal recompete cliff exposes only $117 thousand in combined potential value to ultimate completion within the next twenty-four months, indicating a stable contracting base with limited near-term recompete risk. The division's award footprint is concentrated in in-vitro diagnostic substance manufacturing (101 awards, 68% of total) under NAICS 325221, with secondary concentration in medical equipment and supplies wholesale (15 awards) and reference laboratory testing (5 awards). PSC coding reflects the same concentration: in-vitro diagnostic substances, reagents, test kits (65 awards), medical and surgical instruments and supplies (45 awards), and laboratory equipment (14 awards).